Tomahawk, WI 03/11/2014 (Basicsmedia) – Sangamo Bioscience Inc. (NASDAQ:SGMO) shares saw a slight downward correction (decline by 1.22%) after they surged by 34% a day earlier. A day earlier its prices surged when the company announced early positive results for its SB-728-T gene therapy. The candidate drug targets Human Acquired Immunodeficiency Syndrom using Zinc-finger DNA binding proteins. Des ward dip the stock price touched a new 52 week high point at $22.68.

Sangamo Announced Positive results for HIV Gene therapy

Sangamo Bioscience Inc. (NASDAQ:SGMO)’s drug candidate has shown stable control over replication of the HIV when used in conjunction with a prior dosage of Cytoxan by Bristol Mayers Squibbs (NYSE:BMY). The later is a chemotherapeutic agent. The clinical tests’ protocol was not aided by any sort of antiretroviral therapy. Like most gene bio-therapeutics, the drug targets the human cells and inhibits the development of the CCR-5 protein in the gene structure. Targeted cells instead produce Delta 32 mutated CCR5, which enhances the cell resistance to even the most commonly found strains of HIV virus.

New Process for Greater efficacy

Sangamo Bioscience Inc. (NASDAQ:SGMO) has also developed a new process for gene mutation through messenger RNA. It is currently using deactivated viruses for this purpose, which not only brings in extra costs but is also fragile against immune system’s auto responses. Antibodies of any kind end up developing immunity against deactivated virus. Using RNA means least immune system intervention to the ongoing treatment. It is also more efficient and cost effective production technique. Sangamo Bioscience Inc. (NASDAQ:SGMO) is now trying to optimize Cytoxan’s dosage to enhance efficacy with least side effects. The new method will also be tested on 12 new subjects in an isolated study in order to assess the efficacy of the method of drug delivery.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.